AZNAstraZenecaSigning up patients
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Non-squamous Non-small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,160 (planned)
- Started
- Nov 27, 2024
- Main results expected
- Nov 18, 2030
- Fully finished
- Nov 18, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall survival (OS)
Measured over: Up to approximately 6 years
Progression-free survival (PFS)
Measured over: Up to approximately 6 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06627647 · record last updated 2026-10-28 · checked 2026-11-09 15:47 UTC